Please assess the completion status of the following clinical trial:

Trial Title: Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* measurable metastatic adenocarcinoma of the colon or rectum~* no prior systemic therapy for metastatic disease~* adjuvant therapy must have been completed \>/=12 months prior to recurrence, prior radiotherapy permitted but must have been completed \> 6 months prior to study entry~* must have tumor tissue available for EGFR and thymidine phosphorylase evaluation~* ECOG PS 0-1~* age \>/= 18~* adequate organ function: WBC\>/=3,000, ANC \>/=1,500, platelets\>/= 100,000, total bilirubin \</= 1.5X ULN, AST\&ALT \</= 2.5X ULN, create clearance \>/= 50mL/min~* negative pregnancy test w/in 72 hours of treatment for women of child bearing potential~* ability to understand and willing to sign written ICF~* able to swallow and absorb oral medication~Exclusion Criteria:~* medical or psychiatric condition which would potentially pose risk to patient by participation (i.e. but not limited to:uncontrolled hypertension, MI w/in 6 months,CNS disease, pregnancy or nursing)~* history of neoplasm (other than non-metastatic skin cancer or carcinoma in situ of cervix) w/in 5 years~* surgical procedure (not including closed biopsy or access port placement), open biopsy, significant traumatic injury w/in 28 days of registration or anticipation of need for surgical procedure while on study, fine needle aspiration or core biopsy w/in 7 days of registration~* urine protein:creatinine ration \>/=1.0 at screening~* evidence of bleeding diathesis or coagulopathy (in absence of anticoagulation)~* prior severe infusion reaction to MAB or allergic reaction to capecitabine or oxaliplatin~* underlying neuropathy \>/= grade 2~* TIA or CVA w/in 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab (Type: ACTIVE_COMPARATOR): Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
- Cetuximab, Oxaliplatin, Capecitabine (Type: ACTIVE_COMPARATOR): Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).